Part of Reaction Biology Corporation | 
Contact us to learn more about our assay development and testing services and how we can help you bring safe and effective drug products and biologics to market.
Managing Director and COO
Sven studied Veterinary Medicine at the University of Hannover and graduated Summa cum laude before beginning his career as a Scientist at Medizinische Hochschule Hannover from 1993 to 1998. Sven’s academic pursuit continued as a Postdoc Scientist at Ruhr-University Bochum from 1999 to 2000.
Transitioning seamlessly into the corporate landscape, Sven took on the role of Project Manager at Merck Biomaterials/ Biomet Merck Darmstadt from 2001 to 2006.
In 2006 Sven joined Bioassay as Study Director and was instrumental in managing the corporate development strategy.
Since 2010, Sven has been Managing Director and COO at Bioassay showcasing his dynamic leadership and contributing to completing the acquisition of Peptide Specialty Laboratories GmbH in 2017.
Sven is a seasoned professional with a demonstrated history of excellence in the pharmaceutical and biotechnology industries. With a strong foundation in biochemistry and a passion for scientific innovation, Sven has successfully navigated complex challenges to deliver impactful results throughout his career.
CSO
Axel joined Bioassay in 2007 as Scientists after covering the role of Laboratory Head of Department of Cell and Molecular Biology at Biotest AG. Upon joining Bioassay Axel quickly rose through the ranks and became Managing Director in 2010. In his new role he was involved in the acquisition of Peptide Specialty Laboratories GmbH by Bioassay which he successfully completed in 2017.
Axel earned his magna cum laude Doctorate from the University of Heidelberg, probing angiogenic factors in chronic subdural hematoma.
Immediately after graduating in Biotechnology from the University of Mannheim, Axel worked as Bio-Engineer at BRAIN AG where he perfected his assay development skills.
Axel’s extensive experience includes a profound understanding of GMP, GLP, and FDA approval processes, underscoring his commitment to maintaining the highest standards of quality and integrity. His collaborative approach and aptitude for fostering partnerships have enabled him to cultivate a global network of industry connections.
Axel is currently Managing Director and CSO at Bioassay.
Chief Executive Officer Germany
Sebastian Dempe is biologist by training and received his doctorate degree from the German Cancer Research Center/ University of Heidelberg in 2010 where he was exploiting the capacity of parvovirus H1, currently tested in clinical studies, for the virotherapy of cancer using various preclinical research models. Starting his career in Business Development at ProQinase (2011-2014), he was later appointed as Executive Director Business Development of Crown Bioscience, Inc., leading the company’s European Business Development team until June 2019. Sebastian re-joined ProQinase as CEO/ Managing Director on July 01, 2019.
